相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?
Claudia Angela Maria Fulgenzi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma
Johann von Felden et al.
ONCOGENE (2021)
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
Yi-Ping Hung et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2021)
Therapeutic Targeting of Cancer: Epigenetic Homeostasis
Xiaoyuan Yu et al.
FRONTIERS IN ONCOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma
Kohei Shigeta et al.
HEPATOLOGY (2020)
Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?
Diego Enrico et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
Maria Esperanza Rodriguez-Ruiz et al.
NATURE IMMUNOLOGY (2020)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
Repurposing infectious disease vaccines for intratumoral immunotherapy
Ignacio Melero et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential
Yu-Man Tsui et al.
BRITISH JOURNAL OF CANCER (2020)
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Donghua Shi et al.
CLINICAL CANCER RESEARCH (2020)
Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy
Sirish Dharmapuri et al.
CANCER MEDICINE (2020)
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Yuanjun Lu et al.
MOLECULAR CANCER (2020)
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Kellsye P. Fabian et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune-based therapies for hepatocellular carcinoma
David J. Pinato et al.
ONCOGENE (2020)
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort
Toshihiko Doi et al.
ONCOLOGIST (2020)
Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B
Lung-Yi Mak et al.
JOURNAL OF HEPATOLOGY (2020)
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2020)
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee et al.
LANCET ONCOLOGY (2020)
Soluble PD-L1 and Circulating CD8+PD-1+and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients
G. Mazzaschi et al.
LUNG CANCER (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
John D. Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma
Stephan Spahn et al.
CANCERS (2020)
Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
Michel Montalvo-Casimiro et al.
FRONTIERS IN ONCOLOGY (2020)
Cancer Treatment: An Epigenetic View
Cansu Aydin et al.
GLOBAL MEDICAL GENETICS (2020)
Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors
Paul Winograd et al.
HEPATOLOGY COMMUNICATIONS (2020)
Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer
Dinoop Ravindran Menon et al.
THERANOSTICS (2020)
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma
Xue Han et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma
David Agdashian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Exosomes and Hepatocellular Carcinoma: From Bench to Bedside
Reina Sasaki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Parisa Malekzadeh et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
The microbiome, cancer, and cancer therapy
Beth A. Helmink et al.
NATURE MEDICINE (2019)
Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
Lea Berland et al.
JOURNAL OF THORACIC DISEASE (2019)
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
David J. Pinato et al.
BRITISH JOURNAL OF CANCER (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Fangjun Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
Linda Hammerich et al.
NATURE MEDICINE (2019)
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
Daisuke Sugiura et al.
SCIENCE (2019)
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Jasmine Davda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
Lynn G. Feun et al.
CANCER (2019)
Capecitabine in advanced hepatocellular carcinoma: A multicenter experience
Filippo Pelizzaro et al.
DIGESTIVE AND LIVER DISEASE (2019)
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Clara Depommier et al.
NATURE MEDICINE (2019)
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta et al.
CANCER DISCOVERY (2019)
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma
Ahmed Omar Kaseb et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
R. K. Kelley et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2019)
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma
Yi Zheng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
Yu-Yun Shao et al.
LIVER INTERNATIONAL (2019)
Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Claire Vanpouille-Box et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The role of exosomal PD-L1 in tumor progression and immunotherapy
Feiting Xie et al.
MOLECULAR CANCER (2019)
The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
Boyang Chang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Clinical epigenetics: seizing opportunities for translation
Maria Berdasco et al.
NATURE REVIEWS GENETICS (2019)
CD4+ CD25+ regulatory T cells promote hepatocellular carcinoma invasion via TGF-β1-induced epithelial-mesenchymal transition
Chunying Shi et al.
ONCOTARGETS AND THERAPY (2019)
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
David Tai et al.
CANCERS (2019)
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
Xiufeng Liu et al.
ONCOLOGIST (2019)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
M. E. Rodriguez-Ruiz et al.
ANNALS OF ONCOLOGY (2018)
Targeting Epigenetics in Cancer
Richard L. Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58 (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Vancheswaran Gopalakrishnan et al.
CANCER CELL (2018)
Exosomes in cancer development and clinical applications
Yu-Ling Tai et al.
CANCER SCIENCE (2018)
Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway
Jian Chen et al.
GASTROENTEROLOGY (2018)
Exploring the role of oncolytic viruses in hepatobiliary cancers
Pavan Tenneti et al.
IMMUNOTHERAPY (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma
Po-Hao Feng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
The immunology of hepatocellular carcinoma
Marc Ringelhan et al.
NATURE IMMUNOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells
Chi Ma et al.
SCIENCE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model
Shengbin Shi et al.
TRANSLATIONAL ONCOLOGY (2018)
Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
Anders H. Kverneland et al.
ONCOIMMUNOLOGY (2018)
Complex pattern of immune evasion in MSI colorectal cancer
Mine Ozcan et al.
ONCOIMMUNOLOGY (2018)
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies
Jenny H. Lee et al.
JAMA ONCOLOGY (2018)
Monitoring immune checkpoint regulators as Predictive Biomarkers in hepatocellular carcinoma
Ritu Shrestha et al.
FRONTIERS IN ONCOLOGY (2018)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Vogel et al.
ANNALS OF ONCOLOGY (2018)
Silimarin and Cancer
Christina Liakopoulou et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Potentiating cancer vaccine efficacy in liver cancer
Maria Tagliamonte et al.
ONCOIMMUNOLOGY (2018)
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
Xingxiang Pu et al.
BMC CANCER (2018)
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
Yu-Yang Lin et al.
SEMINARS IN LIVER DISEASE (2018)
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Niki Karachaliou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Zhuting Hu et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature
Rathi N. Pillai et al.
CANCER (2018)
Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in PatientsWith Metastatic Solid Tumors
Shruti Agrawal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy
Leslie S. Kean et al.
IMMUNOLOGICAL REVIEWS (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Wenwen Du et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy et al.
JOURNAL OF HEPATOLOGY (2017)
Myeloid-derived suppressor cellsa new therapeutic target to overcome resistance to cancer immunotherapy
Jason A. Chesney et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE. Mutation
Jun Gong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
New insights into the role of EMT in tumor immune escape
Stephane Terry et al.
MOLECULAR ONCOLOGY (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
The gut microbiome and liver cancer: mechanisms and clinical translation
Le-Xing Yu et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Role of exosomes in treatment of hepatocellular carcinoma
Demetrios Moris et al.
SURGICAL ONCOLOGY-OXFORD (2017)
Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity
Tze Mun Loo et al.
CANCER DISCOVERY (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
Nicolas Guibert et al.
ONCOTARGET (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
Jian-Hong Zhong et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Developments in cancer vaccines for hepatocellular carcinoma
Luigi Buonaguro
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma
Longhao Sun et al.
TUMOR BIOLOGY (2016)
Immune Checkpoint Therapy and the Search for Predictive Biomarkers
Padmanee Sharma
CANCER JOURNAL (2016)
Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen
Emeric Limagne et al.
CANCER RESEARCH (2016)
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
Fabian Finkelmeier et al.
EUROPEAN JOURNAL OF CANCER (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
Zhen Qu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
Zhu Li et al.
MEDICINE (2016)
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
Emilie M. J. van Brummelen et al.
ONCOLOGIST (2016)
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition
Claire F. Friedman et al.
CURRENT ONCOLOGY REPORTS (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
Dong-Qiang Zeng et al.
ONCOTARGET (2016)
Machine Learning Meta-analysis of Large Metagenomic Datasets: Tools and Biological Insights
Edoardo Pasolli et al.
PLOS COMPUTATIONAL BIOLOGY (2016)
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Andrew Gabrielson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
A panoply of errors: polymerase proofreading domain mutations in cancer
Emily Rayner et al.
NATURE REVIEWS CANCER (2016)
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
K. Abiko et al.
BRITISH JOURNAL OF CANCER (2015)
Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma
Daisuke Hokuto et al.
EUROPEAN JOURNAL OF CANCER (2015)
Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
Wenjiang Yan et al.
GUT (2015)
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Matthew M. Gubin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Immunological landscape and immunotherapy of hepatocellular carcinoma
Jesus Prieto et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress
Meriem Hasmim et al.
FRONTIERS IN IMMUNOLOGY (2015)
Redirection of epithelial immune responses by short-chain fatty acids through inhibition of histone deacetylases
May Young Lin et al.
FRONTIERS IN IMMUNOLOGY (2015)
Episensitization: defying time's arrow
BryanT. Oronsky et al.
FRONTIERS IN ONCOLOGY (2015)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Huiping Gao et al.
CLINICAL CANCER RESEARCH (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Enhanced suppressor function of TIM-3+FoxP3+ regulatory T cells
Anne-Sophie Gautron et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+ T-Cell Responses in Hepatocellular Carcinoma
Tobias Flecken et al.
HEPATOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
Evan J. Lipson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
HLA ligandome tumor antigen discovery for personalized vaccine approach
Hans-Georg Rammensee et al.
EXPERT REVIEW OF VACCINES (2013)
Beta-Catenin-NF-κB Interactions in Murine Hepatocytes: A Complex to Die for
Kari Nejak-Bowen et al.
HEPATOLOGY (2013)
Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma
Eishiro Mizukoshi et al.
HEPATOLOGY (2013)
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity
Christine Pasero et al.
IMMUNOLOGY LETTERS (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Nicholas Arpaia et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Sophie Viaud et al.
SCIENCE (2013)
TGF-β Signaling in Myeloid Cells Is Required for Tumor Metastasis
Yanli Pang et al.
CANCER DISCOVERY (2013)
T-cell suppression mediated by regulatory T cells infiltrating hepatic tumors can be overcome by GITRL treatment
Alexander Pedroza-Gonzalez et al.
ONCOIMMUNOLOGY (2013)
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dianne H. Dapito et al.
CANCER CELL (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada et al.
CLINICAL CANCER RESEARCH (2012)
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
Hang Li et al.
HEPATOLOGY (2012)
Cancer-related inflammation: Common themes and therapeutic opportunities
Frances R. Balkwill et al.
SEMINARS IN CANCER BIOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
Feng Shi et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
Tim F. Greten et al.
BMC CANCER (2010)
Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
Wei Zhang et al.
CLINICAL CANCER RESEARCH (2010)
Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients
Valerie Chew et al.
JOURNAL OF HEPATOLOGY (2010)
Cancer Metastasis Is Accelerated through Immunosuppression during Snail-induced EMT of Cancer Cells
Chie Kudo-Saito et al.
CANCER CELL (2009)
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Qiang Gao et al.
CLINICAL CANCER RESEARCH (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
Dong-Ming Kuang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Ceramide triggers budding of exosome vesicles into multivesicular Endosomes
Katarina Trajkovic et al.
SCIENCE (2008)
LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems
Joseph F. Grosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma
Rebecca C. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice
Carsten T. Viehl et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides
LH Butterfield et al.
CLINICAL CANCER RESEARCH (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma
K Fujiwara et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
The danger model: A renewed sense of self
P Matzinger
SCIENCE (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
分享论文
